The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinsn's Disease Progression and Related Dementia

被引:73
|
作者
Compta, Yaroslau [1 ]
Parkkinen, Laura [4 ]
Kempster, Peter [2 ,3 ]
Selikhova, Mariana [5 ]
Lashley, Tammaryn [5 ]
Holton, Janice L. [5 ]
Lees, Andrew J. [5 ]
Revesz, Tamas [5 ]
机构
[1] Hosp Clin Barcelona, CIBERNED, Parkinson Dis & Movement Disorders Unit, Neurol Serv,IDIBAPS, Barcelona, Spain
[2] Monash Med Ctr, Dept Neurosci, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic 3004, Australia
[4] Univ Oxford, Oxford Parkinsons Dis Ctr, Nuffield Dept Clin Neurosci, Oxford, England
[5] UCL, Inst Neurol, Dept Mol Neurosci, Queen Sq Brain Bank Neurol Disorders, London, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
Parkinson's disease; Dementia; Lewy-type pathology; Alzheimer-type pathology; alpha-Synuclein; Tau; Amyloid-beta; Biomarkers; A-BETA; ALZHEIMER-PATHOLOGY; COGNITIVE DECLINE; LEWY; DEPOSITION; RISK; CSF; MARKERS; LOAD;
D O I
10.1159/000354670
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Dementia is one of the milestones of advanced Parkinson's disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications. Objective: The aim of this study was to review the relative importance of Lewy-related alpha-synuclein and Alzheimer's tau and amyloid-beta (A beta) pathologies in disease progression and dementia in PD. Methods: We reviewed studies conducted at the Queen Square Brain Bank, Institute of Neurology, University College London, using large PD cohorts. Results: Cortical Lewy- and Alzheimer-type pathologies are associated with milestones of poorer prognosis and with non-tremor predominance, which have been, in turn, linked to dementia. The combination of these pathologies is the most robust neuropathological substrate of PD-related dementia, with cortical A beta burden determining a faster progression to dementia. Conclusion: The shared relevance of these pathologies in PD progression and dementia is in line with experimental data suggesting synergism between a-synuclein, tau and A beta and with studies testing these proteins as disease biomarkers, hence favouring the eventual testing of therapeutic strategies targeting these proteins in PD. (C) 2013 S. Karger AG, Basel
引用
收藏
页码:154 / 156
页数:3
相关论文
共 50 条
  • [41] Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
    Elvira Valera
    Brian Spencer
    Eliezer Masliah
    Neurotherapeutics, 2016, 13 : 179 - 189
  • [42] Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation
    He, Zhuohao
    Guo, Jing L.
    McBride, Jennifer D.
    Narasimhan, Sneha
    Kim, Hyesung
    Changolkar, Lakshmi
    Zhang, Bin
    Gathagan, Ronald J.
    Yue, Cuiyong
    Dengler, Christopher
    Stieber, Anna
    Nitla, Magdalena
    Coulter, Douglas A.
    Abel, Ted
    Brunden, Kurt R.
    Trojanowski, John Q.
    Lee, Virginia M-Y
    NATURE MEDICINE, 2018, 24 (01) : 29 - +
  • [43] Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
    Valera, Elvira
    Spencer, Brian
    Masliah, Eliezer
    NEUROTHERAPEUTICS, 2016, 13 (01) : 179 - 189
  • [44] Significant Overlap of α-Synuclein, Amyloid-β, and Phospho-Tau Pathologies in Neuropathological Diagnosis of Lewy-related Pathology: Evidence from China Human Brain Bank
    Cong, Cong
    Zhang, Wanying
    Qian, Xiaojing
    Qiu, Wenying
    Ma, Chao
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 80 (01) : 447 - 458
  • [45] CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
    Bibl, M
    Mollenhauer, B
    Esselmann, H
    Lewczuk, P
    Klafki, HW
    Sparbier, K
    Smirnov, A
    Cepek, L
    Trenkwalder, C
    Rüther, E
    Kornhuber, J
    Otto, M
    Wiltfang, J
    BRAIN, 2006, 129 : 1177 - 1187
  • [46] A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies
    Lathuiliere, Aurelien
    Laversenne, Vanessa
    Astolfo, Alberto
    Kopetzki, Erhard
    Jacobsen, Helmut
    Stampanoni, Marco
    Bohrmann, Bernd
    Schneider, Bernard L.
    Aebischer, Patrick
    BRAIN, 2016, 139 : 1587 - 1604
  • [47] New Treatment for Alzheimer's Disease, Kamikihito, Reverses Amyloid-β-Induced Progression of Tau Phosphorylation and Axonal Atrophy
    Watari, Hidetoshi
    Shimada, Yutaka
    Tohda, Chihiro
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [48] Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease
    Alison K. Ower
    Christoforos Hadjichrysanthou
    Luuk Gras
    Jaap Goudsmit
    Roy M. Anderson
    Frank de Wolf
    European Journal of Epidemiology, 2018, 33 : 657 - 666
  • [49] Pyroglutamylated Amyloid-β correlates with Hyperphosphorylated Tau and Severity of Alzheimer's Disease
    Attems, Johannes
    Walker, Lauren
    Santic, Radmila
    Upadhaya, Ajeet Rijal
    Colloby, Sean
    Thal, Dietmar
    Thomas, Alan
    Schneeberger, Achim
    Mandler, Markus
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2014, 73 (06): : 587 - 587
  • [50] Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
    Yuan Cheng
    Jun-Rong Ren
    Jie-Ming Jian
    Chen-Yang He
    Man-Yu Xu
    Gui-Hua Zeng
    Cheng-Rong Tan
    Ying-Ying Shen
    Wang-Sheng Jin
    Dong-Wan Chen
    Hui-Yun Li
    Xu Yi
    Yuan Zhang
    Xian-Le Bu
    Yan-Jiang Wang
    Translational Psychiatry, 12